Sarepta Therapeutics, Inc.
SRPTNasdaq
$17.22
↓ -0.1%Jul 17 close · end-of-day
Price
1Y↓ -6.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.1B
Enterprise Value
$2.3B
P/E
50.6
P/S
1.0
P/B
1.4
EV/EBITDA
547.2
PEG
—
FCF Yield
5.5%
Dividend Yield
—
Revenue (TTM)
$2.2B
Net Income (TTM)
$65.1M
Free Cash Flow (TTM)
$114.9M
Gross Margin
—
Operating Margin
-1.9%
Net Margin
3.0%
ROE
4.3%
ROIC
-2.4%
Debt / Equity
0.6
Net Cash
-$185.0M
Return 1Y
-21.6%
Company profile
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio.
- CEO
- Douglas S. Ingram
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 840
- Headquarters
- Massachusetts
- Website
- sarepta.com
Earnings
SRPT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$730.8M↓ -1.9%
Diluted EPS$2.88↓ -162.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $540.1M | $701.9M | $933.0M | $1.2B | $1.9B | $2.2B |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$564.2M | -$459.7M | -$536.2M | -$267.8M | $218.1M | -$699.8M |
| Net income | -$554.1M | -$418.8M | -$703.5M | -$536.0M | $235.2M | -$713.4M |
| Diluted EPS | -$7.11 | -$5.15 | -$8.03 | -$5.80 | $2.34 | -$7.13 |
| Operating cash flow | $107.5M | -$443.2M | -$325.3M | -$501.0M | -$205.8M | -$205.5M |
| Free cash flow | $25.3M | -$481.7M | -$356.2M | -$577.1M | -$342.7M | -$307.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -104.5% | -65.5% | -57.5% | -21.5% | 11.5% | -31.8% |
| Net margin | -102.6% | -59.7% | -75.4% | -43.1% | 12.4% | -32.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $362.9M | $467.2M | $658.4M | $744.9M | $611.1M | $399.4M | $442.9M | $730.8M |
| Gross profit | $316.0M | $338.1M | $505.9M | $474.0M | $360.6M | $219.3M | -$29.1M | — |
| Operating income | -$701,000.00 | $22.2M | $161.7M | -$300.4M | $115.6M | -$103.4M | -$411.6M | $358.4M |
| Net income | $6.5M | $33.6M | $159.0M | -$447.5M | $196.9M | -$50.6M | -$412.2M | $331.0M |
| Diluted EPS | $0.07 | $0.34 | $1.50 | -$4.60 | $1.89 | -$0.50 | -$3.93 | $2.88 |
| Operating cash flow | $14.9M | -$70.7M | $92.0M | -$583.4M | $261.3M | -$14.6M | $131.2M | -$202.7M |
| Free cash flow | -$14.2M | -$108.0M | $54.0M | -$627.1M | $229.5M | -$37.5M | $127.6M | -$204.8M |
| Gross margin | 87.1% | 72.4% | 76.8% | 63.6% | 59.0% | 54.9% | -6.6% | — |
| Operating margin | -0.2% | 4.8% | 24.6% | -40.3% | 18.9% | -25.9% | -92.9% | 49.0% |
| Net margin | 1.8% | 7.2% | 24.2% | -60.1% | 32.2% | -12.7% | -93.1% | 45.3% |
Company news
Jul 20, 2026
Jul 17, 2026
Jul 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.